UBS AM’s Repros Therapeutics Inc. RPRX Stock Holding History

UBS AM’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-7,500	Closed	-$201K	–	2637
2013 Q3	$201K	Buy	+7,500	New	+$161K	﹤0.01%	2324

Other funds holding RPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM's RPRX Position: Q4 2013 in Review

UBS AM sold out of Repros Therapeutics Inc. (RPRX) in Q4 2013, closing a stake of 7,500 shares — an estimated $201K sold.

UBS AM first reported a position in RPRX in Q3 2013 and held it in 1 quarter. The position peaked at $201K in Q3 2013. 79 funds tracked by Wall St. Rank hold RPRX as of Q4 2013.

UBS AM reported no remaining Repros Therapeutics Inc. position as of Q4 2013 after selling out during the quarter.
UBS AM sold 7,500 Repros Therapeutics Inc. shares in Q4 2013, an estimated $201K.
UBS AM first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 1 quarter.
UBS AM's Repros Therapeutics Inc. position peaked at $201K in Q3 2013.
79 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2013.

Based on UBS AM's 13F filing for Q4 2013, filed 31 Jan 2014.